Neopeutics Takes Home the Frost & Sullivan 2015 Technology Leadership Award for its Outstanding Innovations in the Enhanced Drug Discovery Market
Neopeutics’ integrative strategy demonstrates its commitment to accelerate the delivery of new nature-based pharmaceuticals and therapeutics
MOUNTAIN VIEW, Calif. — September 23, 2015, — Frost & Sullivan honored Neopeutics, Inc. with the 2015 North America Frost & Sullivan Award for Technology Leadership at its glittering black-tie event, the 2015 Excellence in Best Practices Awards Gala, at the Hilton San Diego, on 10th March. Izza Jahari, PhD., Co-founder, CEO and Executive Director, Neopeutics, Inc., accepted the Award that was presented in recognition of the company’s robust, cost-effective, and easily adaptable set of drug discovery instruments.
Click here for the full multimedia experience of this release – http://bit.ly/1PpNkut
Neopeutics uniquely focuses on agents that are catalogued as failing compounds in the early stages of the drug discovery process, enabling customers to lower attrition rates and save drug development costs. Frost & Sullivan recognizes the integrity of the company in partnering with its customers at every stage of the process, improving both affordability and efficacy, and fostering smooth relations with regulatory bodies, even with regard to the use of nature-based products.
“One of the main distinguishing factors of Neopeutics is its commitment toward introducing natural herbal products, pharmaceuticals, and therapeutics in the global biopharmaceutical market,” said Frost & Sullivan Industry Analyst Cecilia Van Cauwenberghe. “The company is achieving this through the development of a multi-service drug discovery hub for nature-based therapeutics, which delivers unique, affordable, high-standard quality assurance and control services.”
Additionally, Neopeutics’ end-to-end set of bioinformatics tools and expertise greatly assists the development of flexible, customized software tools such as genomics and proteomics platforms for drug screening and discovery.
Neopeutics’ technology platform has been commercialized not only among large pharmaceutical companies, but also small and medium enterprises, aiding the analysis of nature-based herbal products and nutraceuticals. During the screening phase, bioactive ingredients are extracted, separated, analyzed, and then profiled according to their potential therapeutic action.
“Neopeutics’ technology platform speeds up the identification of new therapeutic candidates by elucidating the mechanisms of action and signaling pathways, followed by the chemical agents in several in silico models,” noted Van Cauwenberghe. “Such early screening of compounds helps to guarantee a good safety profile for the agents under study.”
The company’s highly efficient and accurate technology helps determine the behavior of a wide range of compounds with their targets and allows the provision of quality assurance (QA) services as a natural extension of its services. Since smaller manufacturers do not possess the facilities, financial resources, or expertise to perform QA, they will benefit greatly from Neopeutics’ techno-marketing. Similarly, it aids government regulatory agencies in establishing the mode of action and safety profiles of herbal medication, which is an important step in the regulatory and approval processes.
“Neopeutics is currently using a first-generation version of its proprietary software package of bioinformatics software tools for the drug screening market, while simultaneously working on launching its second-generation package,” observed Van Cauwenberghe. “It also leverages its bioinformatics capabilities to add value to other in-house, tailor-made solutions and enrich key components. Most of these services are coupled with assessment programs, as well as data analysis and interpretation services.”
Furthermore, the company has strategic advantages in terms of both geography and business development. Its two main locations in the United States and Malaysia are ideal to help it enhance business development activities with the major regional players.
For understanding the needs and goals of its clients, and designing an operational strategy that allows it to be positioned as a technology incubator, Frost & Sullivan is pleased to present Neopeutics with the 2015 North America Frost & Sullivan Award for Technology Leadership.
Frost & Sullivan Best Practices Awards recognize companies in a variety of regional and global markets for demonstrating outstanding achievement and superior performance in areas such as leadership, technological innovation, customer service and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analysis and extensive secondary research to identify best practices in the industry.
About Neopeutics, Inc.
Neopeutics is an early stage drug discovery contract research partner that offers our partners and clients a robust and cost effective set of pre-clinical drug discovery tools. Our proprietary ChemoMAP® technology package is perfectly suited for “failing” compounds in the early stages of drug discovery, thereby helping to achieve notable savings in drug development costs. In addition, our discovery platform can also help our clients enhance the accuracy and speed of their “hit” identification process as well as elucidate the mode of action and confirm the efficacy and safety of their in-development and on-the-market products, thereby helping to improve drug safety and build consumer confidence.
As systems biology opens up limitless possibilities in drug discovery, we invite you to explore the horizon of drug discovery with us.
For more information, please visit www.neopeutics.com, or contact us at [email protected]
